[go: up one dir, main page]

AR072976A1 - Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo - Google Patents

Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo

Info

Publication number
AR072976A1
AR072976A1 ARP090103029A AR072976A1 AR 072976 A1 AR072976 A1 AR 072976A1 AR P090103029 A ARP090103029 A AR P090103029A AR 072976 A1 AR072976 A1 AR 072976A1
Authority
AR
Argentina
Prior art keywords
viruses
infectious bronchitis
virus
prepare
vaccine composition
Prior art date
Application number
Other languages
English (en)
Inventor
Geert Jan Boelm
Bastiana Geertruida Elisabeth Stuurman
Harmen Jacob Geerligs
Cindy Aleida Maria Meinders
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR072976A1 publication Critical patent/AR072976A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/08—Inactivation or attenuation by serial passage of virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Virus de bronquitis infecciosa (IB) derivados de un genotipo recientemente identificado del virus IB conocido como IB-QX, o de los virus que se relacionan genéticamente con IB-QX, referenciados aquí como virus similares a IB-QX. Los virus IB pueden ser vivos y atenuados o inactivos. Los virus vivos, atenuados IB, se pueden producir mediante el pase sucesivo de un virus similar a IB-QX. Los virus IB son utiles como, entre otras cosas, vacunas contra IB-QX y virus similar a IB-QX. Por lo tanto, las cepas de vacuna conocidas de los virus IB han probado ser insuficientes para proteger contra la bronquitis infecciosa originada por IB-QX y virus similares a IB-QX.
ARP090103029 2008-08-08 2009-08-06 Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo AR072976A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8722808P 2008-08-08 2008-08-08

Publications (1)

Publication Number Publication Date
AR072976A1 true AR072976A1 (es) 2010-10-06

Family

ID=41211689

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103029 AR072976A1 (es) 2008-08-08 2009-08-06 Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo

Country Status (26)

Country Link
US (1) US9296991B2 (es)
EP (1) EP2331682B1 (es)
JP (3) JP2011530294A (es)
KR (2) KR20110038181A (es)
CN (1) CN102239252B (es)
AR (1) AR072976A1 (es)
AU (1) AU2009279528A1 (es)
BR (1) BRPI0917447A2 (es)
CA (1) CA2732822C (es)
CL (1) CL2011000262A1 (es)
CO (1) CO6351810A2 (es)
CY (1) CY1121567T1 (es)
DK (1) DK2331682T3 (es)
ES (1) ES2702089T3 (es)
HU (1) HUE041481T2 (es)
LT (1) LT2331682T (es)
ME (1) ME01270B (es)
MX (1) MX339731B (es)
PL (1) PL2331682T3 (es)
PT (1) PT2331682T (es)
RU (1) RU2568053C2 (es)
SI (1) SI2331682T1 (es)
TR (1) TR201819340T4 (es)
UA (1) UA103330C2 (es)
WO (1) WO2010017440A1 (es)
ZA (1) ZA201100849B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016507225A (ja) 2012-12-18 2016-03-10 メリアル インコーポレイテッド Ｉｂｖ、ｃｓｆｖ及びｎｄｖの高解像度融解遺伝子型決定
CN103028112B (zh) * 2012-12-31 2014-08-06 青岛易邦生物工程有限公司 一种鸡新城疫和传染性支气管炎二联活疫苗
CN103146654B (zh) * 2013-03-25 2014-07-30 浙江诺倍威生物技术有限公司 一株人工弱化的鸡传染性支气管炎病毒及其应用
CN109152829A (zh) 2016-06-02 2019-01-04 硕腾服务有限责任公司 针对传染性支气管炎的疫苗
CN108950068B (zh) * 2018-07-18 2021-05-07 浙江大学 一种鸡传染性支气管炎病毒qx型毒株鉴别检测试剂盒
JP7206383B2 (ja) * 2018-10-31 2023-01-17 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 異種スパイクタンパク質を有する４／９１ ｉｂｖワクチン
WO2024019579A1 (ko) * 2022-07-22 2024-01-25 주식회사 카브 닭전염성기관지염바이러스 약독화주 및 이를 포함하는 백신조성물
KR102717877B1 (ko) * 2023-06-16 2024-10-16 주식회사 지나이너 외래 qx 유사 바이러스 스파이크 단백질을 포함하는 전염성 기관지염 키메라 바이러스 및 이를 포함하는 백신 조성물
WO2025055902A1 (en) * 2023-09-11 2025-03-20 Boehringer Ingelheim Vetmedica (China) Co., Ltd. Attenuated infectious bronchitis virus and a vaccine comprising the same
GB2640725A (en) 2024-05-03 2025-11-05 Genera Dionicko Drustvo Vaccine
CN118546258B (zh) * 2024-06-03 2024-11-29 中国动物卫生与流行病学中心 一种鸡传染性支气管炎病毒抗原表位融合肽及其在间接elisa检测中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867975A (en) * 1988-01-27 1989-09-19 University Of Delaware Live attenuated temperature-sensitive avian infectious bronchitis virus vaccines and preparation and use thereof
US5037650A (en) * 1988-03-08 1991-08-06 Akzo N.V. Live combination vaccine
DK0639640T3 (da) * 1993-07-30 2001-01-02 Akzo Nobel Nv Fjerkrævaccine indeholdende smitsomt bronchitis-virus serotype 4/91
JPH07206705A (ja) * 1993-11-03 1995-08-08 American Cyanamid Co 生インオボ（ｉｎ ｏｖｏ）ワクチン
US20010046500A1 (en) 2000-02-29 2001-11-29 Berend Jongsma In ovo protection against infectious bronchitis
ES2333223T3 (es) 2003-03-03 2010-02-18 Intervet International B.V. Virus de la bronquitis infecciosa que contiene un gen punta modificado.
US7291342B2 (en) 2003-05-19 2007-11-06 Intervet International B.V. Infectious bronchitis virus vaccine

Also Published As

Publication number Publication date
ES2702089T3 (es) 2019-02-27
JP2017212976A (ja) 2017-12-07
KR101732240B1 (ko) 2017-05-02
ME01270B (me) 2013-06-20
PL2331682T3 (pl) 2019-03-29
UA103330C2 (ru) 2013-10-10
BRPI0917447A2 (pt) 2015-12-01
HK1159164A1 (zh) 2012-07-27
US9296991B2 (en) 2016-03-29
MX2011001514A (es) 2011-03-29
TR201819340T4 (tr) 2019-01-21
CL2011000262A1 (es) 2011-05-06
RU2011104201A (ru) 2012-08-20
EP2331682A1 (en) 2011-06-15
JP2011530294A (ja) 2011-12-22
EP2331682B1 (en) 2018-10-24
CO6351810A2 (es) 2011-12-20
AU2009279528A1 (en) 2010-02-11
US20110305726A1 (en) 2011-12-15
JP2015144605A (ja) 2015-08-13
PT2331682T (pt) 2018-12-19
CA2732822A1 (en) 2010-02-11
ZA201100849B (en) 2015-10-28
HUE041481T2 (hu) 2019-05-28
MX339731B (es) 2016-06-08
SI2331682T1 (sl) 2019-01-31
CN102239252A (zh) 2011-11-09
CN102239252B (zh) 2015-04-15
CY1121567T1 (el) 2020-05-29
LT2331682T (lt) 2018-12-10
KR20150020623A (ko) 2015-02-26
CA2732822C (en) 2016-09-20
WO2010017440A1 (en) 2010-02-11
KR20110038181A (ko) 2011-04-13
RU2568053C2 (ru) 2015-11-10
DK2331682T3 (en) 2018-12-10
JP6397539B2 (ja) 2018-09-26

Similar Documents

Publication Publication Date Title
AR072976A1 (es) Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo
CL2016001580A1 (es) Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
MX2018004916A (es) Vacuna contra el virus de la influenza de amplio espectro.
PE20150356A1 (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
UY37563A (es) Aislados de bacillus y usos de los mismos
MY156422A (en) Methods and compositions for live attenuated viruses
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
ECSP15011603A (es) Subunidades de vacunas de inmersión para peces
MX2020002151A (es) Compuestos antivirales.
MX383531B (es) Novedoso bacteriófago clo-pep-1 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
UY32274A (es) Pestivirus quimericos
EA201391515A1 (ru) Инактивированная вакцина вируса денге
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
CR20130054A (es) Procesos para preparar compuestos antivirales
EA201390812A1 (ru) Лиофилизированные вирусные составы
PE20140871A1 (es) COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA
CL2016000300A1 (es) Métodos terapéuticos
CO6290645A2 (es) Compuesto para el tratamiento de la hepatitis c
GT201100241A (es) Proceso para preparar compuestos antivirales

Legal Events

Date Code Title Description
FC Refusal